Aclaris Therapeutics, Inc. (ACRS) Starts Phase 2b Trial in Lichen Planus

Aclaris Therapeutics (ACRS) began a Phase 2b trial of modzatinib for lichen planus, enrolling 100 participants. The FDA granted Fast Track designation. The trial is randomized and placebo-controlled, focusing on oral erosive lichen planus first.

Original reporting
Published Nov 16, 2026, 8:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 8:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aclaris Therapeutics, Inc. (ACRS) Starts Phase 2b Trial in Lichen Planus — source image
Decision brief

The 30-second read

$ACRSBullishMed
01

Why it matters

Aclaris gains a regulatory milestone and a potential market differentiator in lichen planus treatment.

02

Market read

First‑report trial start provides a fresh catalyst for ACRS and may influence peer valuations.

03

What to watch

Fast Track designation may accelerate regulatory review, but enrollment risk remains.

Relevance 8/10Novelty 8/10Timing: today

Background

Phase 2b trials test efficacy and safety in a larger patient group after Phase 1 establishes dosing.

Company-level read

Ticker impact

$ACRSBullishMedium confidence
Context

Aclaris Therapeutics announced the start of a Phase 2b trial for modzatinib in lichen planus, a first‑report clinical development update.

Expected impact

potential upside as investors price in future efficacy data

Evidence & confidence

Phase 2b starts are material for biotech valuations; no data yet, but market typically reacts positively to trial progress.

Market effects

May boost sentiment for dermatology and rare‑disease biotech peers.

Limited to US biotech sector.

Low global impact beyond niche therapeutic area.

Counterpoint

If the trial fails to meet endpoints, the stock could face sharp downside.

Key entities

  • Aclaris Therapeutics, Inc.

    Biopharma developing modzatinib for dermatologic conditions.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.